Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2005 3
2006 1
2007 3
2008 5
2009 1
2010 1
2011 2
2013 1
2014 2
2015 1
2016 1
2017 2
2018 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Modernizing Human Cancer Risk Assessment of Therapeutics.
Fielden MR, Ward LD, Minocherhomji S, Nioi P, Lebrec H, Jacobson-Kram D. Fielden MR, et al. Trends Pharmacol Sci. 2018 Mar;39(3):232-247. doi: 10.1016/j.tips.2017.11.005. Epub 2017 Dec 11. Trends Pharmacol Sci. 2018. PMID: 29242029 Review.
Iconix Biosciences, Inc.
Fielden MR, Halbert DN. Fielden MR, et al. Pharmacogenomics. 2007 Apr;8(4):401-5. doi: 10.2217/14622416.8.4.401. Pharmacogenomics. 2007. PMID: 17391077
Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat.
Fielden MR, Adai A, Dunn RT 2nd, Olaharski A, Searfoss G, Sina J, Aubrecht J, Boitier E, Nioi P, Auerbach S, Jacobson-Kram D, Raghavan N, Yang Y, Kincaid A, Sherlock J, Chen SJ, Car B; Predictive Safety Testing Consortium, Carcinogenicity Working Group. Fielden MR, et al. Toxicol Sci. 2011 Nov;124(1):54-74. doi: 10.1093/toxsci/kfr202. Epub 2011 Aug 2. Toxicol Sci. 2011. PMID: 21813463
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat.
Fielden MR, Nie A, McMillian M, Elangbam CS, Trela BA, Yang Y, Dunn RT 2nd, Dragan Y, Fransson-Stehen R, Bogdanffy M, Adams SP, Foster WR, Chen SJ, Rossi P, Kasper P, Jacobson-Kram D, Tatsuoka KS, Wier PJ, Gollub J, Halbert DN, Roter A, Young JK, Sina JF, Marlowe J, Martus HJ, Aubrecht J, Olaharski AJ, Roome N, Nioi P, Pardo I, Snyder R, Perry R, Lord P, Mattes W, Car BD; Predictive Safety Testing Consortium; Carcinogenicity Working Group. Fielden MR, et al. Toxicol Sci. 2008 May;103(1):28-34. doi: 10.1093/toxsci/kfn022. Epub 2008 Feb 14. Toxicol Sci. 2008. PMID: 18281259
Direct quantification of in vivo mutagenesis and carcinogenesis using duplex sequencing.
Valentine CC 3rd, Young RR, Fielden MR, Kulkarni R, Williams LN, Li T, Minocherhomji S, Salk JJ. Valentine CC 3rd, et al. Among authors: fielden mr. Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33414-33425. doi: 10.1073/pnas.2013724117. Epub 2020 Dec 14. Proc Natl Acad Sci U S A. 2020. PMID: 33318186 Free PMC article.
Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D.
Low JD, Bartberger MD, Chen K, Cheng Y, Fielden MR, Gore V, Hickman D, Liu Q, Allen Sickmier E, Vargas HM, Werner J, White RD, Whittington DA, Wood S, Minatti AE. Low JD, et al. Among authors: fielden mr. Medchemcomm. 2017 Apr 27;8(6):1196-1206. doi: 10.1039/c7md00106a. eCollection 2017 Jun 1. Medchemcomm. 2017. PMID: 30108829 Free PMC article.
26 results